M.I.T. and the Whitehead Institute file the initial provisional patent application to a novel class of dendrimer nanoparticles: Compositions and Methods for Modified Dendrimer Nanoparticle Delivery.

M.I.T. and Whitehead colleagues delivered a protective Zika Virus vaccine candidate to our collaborators at the United States Army Medical Research Institute of Infectious Diseases. Chahal JS, Fang T, Woodham AW, Khan OF, Ling J, Anderson DG, Ploegh HL. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep. 2017 Mar 21;7(1):252. 

Tiba moves into a state-of-the-art 20,000 sq.ft. laboratory space and expands the team with new hires of our original M.I.T. academic colleagues.

Leveraging the original academic findings and ongoing discovery, Tiba initiates a new round of patent filings that further extend our library of novel chemistries to a broader range of applications.

Tiba establishes a research collaboration with the University of Pittsburg’s Center for Vaccine Research, extending to Carnegie Mellon University.  This is followed by a funded research project with the King Abdullah University of Science and Technology to develop a novel prime-boost vaccine prototype.

The NIH Collaborative Influenza Vaccine Innovation Centers (CIVIC) initiative invited Tiba to join the effort to develop a novel universal influenza vaccine candidate, in collaboration with Prof. Florian Krammer of the Icahn School of Medicine at Mount Sinai.  Carried into 2022, this effort extends to novel mucosal delivery of RNA vaccines with an expanding team of academic collaborators.

Collaborators from the NIH Collaborative Influenza Vaccine Innovation Centers (CIVICs) consortium showed that nasal delivery of an RNABL vaccine induced adaptive immune responses in the respiratory tracts of mice. See Künzli et al., Sci Immunol. Vol. 7 No. 78 (Dec 2022). Künzli et al., Sci Immunol. Vol. 7 No. 78 (Dec 2022).

Tiba Biotech secures an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.  This three year, $3 million funding will leverage an earlier program, toward a pre-IND filing with the FDA.